Profusa, Inc. Common Stock (NASDAQ:PFSA) — Market Cap & Net Worth
Market Cap & Net Worth: Profusa, Inc. Common Stock (PFSA)
Profusa, Inc. Common Stock (NASDAQ:PFSA) has a market capitalization of $1.18 Million ($1.18 Million) as of June 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #30409 globally and #6104 in its home market, demonstrating a -7.70% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Profusa, Inc. Common Stock's stock price $0.25 by its total outstanding shares 4660268 (4.66 Million). Review how much debt does Profusa, Inc. Common Stock carry to assess the company's total debt and financial obligations.
Profusa, Inc. Common Stock Market Cap History: 2025 to 2026
Profusa, Inc. Common Stock's market capitalization history from 2025 to 2026. Data shows growth from $488.40K to $1.18 Million (0.00% CAGR).
Profusa, Inc. Common Stock Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Profusa, Inc. Common Stock's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of PFSA by Market Capitalization
Companies near Profusa, Inc. Common Stock in the global market cap rankings as of June 18, 2026.
Key companies related to Profusa, Inc. Common Stock by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #149 globally with a market cap of $153.89 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #212 globally with a market cap of $115.24 Billion USD.
- Medtronic plc (SA:MDTC34): Ranked #236 globally with a market cap of $104.84 Billion USD ( R$534.32 Billion BRL).
- Medtronic PLC (NYSE:MDT): Ranked #252 globally with a market cap of $100.32 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #149 | Abbott Laboratories | NYSE:ABT | $153.89 Billion | $88.50 |
| #212 | Stryker Corporation | NYSE:SYK | $115.24 Billion | $301.14 |
| #236 | Medtronic plc | SA:MDTC34 | $104.84 Billion | R$208.39 |
| #252 | Medtronic PLC | NYSE:MDT | $100.32 Billion | $78.14 |
Profusa, Inc. Common Stock Historical Marketcap From 2025 to 2026
Between 2025 and today, Profusa, Inc. Common Stock's market cap moved from $488.40K to $ 1.18 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.18 Million | +142.56% |
| 2025 | $488.40K | -- |
End of Day Market Cap According to Different Sources
On Jun 18th, 2026 the market cap of Profusa, Inc. Common Stock was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.18 Million USD |
| MoneyControl | $1.18 Million USD |
| MarketWatch | $1.18 Million USD |
| marketcap.company | $1.18 Million USD |
| Reuters | $1.18 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Profusa, Inc. Common Stock
Profusa, Inc., a digital health technology company, develops bioengineered sensors for body to detect and continuously transmit clinical-grade data for personal and medical use in the United States. It offers the Lumee Oxygen Platform to monitor compromised tissue for peripheral artery disease, chronic wounds, and reconstructive surgery. The company researches and develops the Lumee Glucose Platf… Read more